Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CRBPBullishIndustry Newsnews

High materiality8/10

Corbus CRB-913 shows meaningful weight loss, signaling potential oral obesity therapy

Sep 14, 2026, 11:24 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive topline efficacy with favorable safety; upcoming ObesityWeek data and FDA Phase 2 plans present clear near-term catalysts.

AI summary

What happened, with direct paths to the underlying reporting

Corbus reported topline data from CANYON-1 Phase 1b for CRB-913, an oral CB1 inverse agonist for obesity. At 12 weeks, the 60 mg cohort showed a 5.0% placebo-adjusted weight loss, with fewer GI adverse events than oral GLP-1 drugs and no suicidality observed. The company will present full data at ObesityWeek 2026 and pursue FDA discussions to launch a Phase 2 monotherapy in 2027, with potential combo opportunities.

CRBP reports CANYON-1 topline results for CRB-913; weight loss significant.
60 mg dose: 5.0% placebo-adjusted weight loss over 12 weeks.
Safety favorable with fewer GI AEs versus oral GLP-1 drugs.
Next steps: FDA consult for Phase 2; data at ObesityWeek 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Corbus CRB-913 shows meaningful weight loss, signaling potential oral obesity therapy

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now